Literature DB >> 29113665

Endoscopic assessment of tumor regression after preoperative chemoradiotherapy as a prognostic marker in locally advanced rectal cancer.

Dae Kyung Sohn1, Kyung Su Han1, Byung Chang Kim1, Chang Won Hong1, Hee Jin Chang1, Ji Yeon Baek1, Min Ju Kim1, Sung Chan Park1, Jae Hwan Oh1, Dae Yong Kim2.   

Abstract

PURPOSE: This study was designed to evaluate tumor regression endoscopic criteria for predicting the post-chemoradiotherapy (CRT) prognosis of patients with locally advanced rectal cancer.
MATERIAL AND METHODS: A total of 425 patients with rectal cancer who received radical surgery after CRT were included in this study. All patients were divided into two groups according to post-CRT preoperative endoscopic findings: 1) good response (E-GR): scar, telangiectasia, or erythema; 2) minimal or no response (E-MR): nodules, ulcers, strictures, or remnant tumor. Cox proportional hazard models were used to analyze the effect of preoperative clinicopathological variables on disease-free survival (DFS) and overall survival (OS).
RESULTS: The independent prognostic factors for DFS were tumor location less than 5 cm from anal verge (hazard ratio [HR] 1.92, 95% confidence interval [CI] 1.27 to 2.88), pre-CRT carcinoembryonic antigen (CEA) > 5 ng/mL (HR 2.10, 95% CI 1.41 to 3.14), histologic high grade (HR 2.96, 95% CI 1.51 to 5.81), and E-GR (HR 0.26, 95% CI 0.08 to 0.83). The independent prognostic factors for OS were age over 65 years, tumor location, pre-CRT CEA, histologic grade, and E-GR (HR 0.13, 95% CI 0.02 to 0.99).
CONCLUSIONS: Post-CRT endoscopic findings were predictors of prognosis in patients with rectal cancer. If endoscopic findings are simultaneously used with certain preoperative prognostic factors, rectal cancer patients will potentially have more treatment options.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Chemoradiotherapy; Endoscopy; Neoadjuvant therapy; Rectal neoplasms; Response evaluation criteria in solid tumors

Mesh:

Year:  2017        PMID: 29113665     DOI: 10.1016/j.suronc.2017.09.002

Source DB:  PubMed          Journal:  Surg Oncol        ISSN: 0960-7404            Impact factor:   3.279


  3 in total

1.  A prospective clinical study assessing the presence of exfoliated cancer cells and rectal washout including tumors in patients who receive neoadjuvant chemoradiotherapy for rectal cancer.

Authors:  Kazutake Okada; Sotaro Sadahiro; Yutaro Kamei; Lin Fung Chan; Takashi Ogimi; Hiroshi Miyakita; Gota Saito; Akira Tanaka; Toshiyuki Suzuki
Journal:  Surg Today       Date:  2019-10-21       Impact factor: 2.549

2.  Creation of a rectal cancer registry in Italy by the Advanced International Mini-Invasive Surgery (AIMS) academy clinical research network.

Authors:  Giulio M Mari; Pietro Achilli; Dario Maggioni; Jacopo Crippa; Andrea T M Costanzi; Mauro A Scotti; Vittorio Giardini; Mattia Garancini; Eugenio Cocozza; Giacomo Borroni; Ilaria Benzoni; Mario Martinotti; Luigi Totaro; Matteo Origi; Michele Mazzola; Giovanni Ferrari; Antonio Ziccarelli; Roberto Petri; Vincenzo Bagnardi; Giacomo Pugliese; Antonello Forgione; Raffaele Pugliese
Journal:  F1000Res       Date:  2019-10-10

3.  The clinical significance of simple endoscopic scoring of patients with rectal cancer after concurrent chemoradiotherapy.

Authors:  Ji Hun Choi; Jae Hyun Kim; Do Hyeong Lee; Sanghwan Byun; Kyoungwon Jung; Sung Eun Kim; Won Moon; Moo In Park; Seun Ja Park
Journal:  J Gastrointest Oncol       Date:  2019-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.